0 117

Cited 3 times in

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Authors
 Byoung Chul Cho  ;  Busayamas Chewaskulyong  ;  Ki Hyeong Lee  ;  Arunee Dechaphunkul  ;  Virote Sriuranpong  ;  Fumio Imamura  ;  Naoyuki Nogami  ;  Takayasu Kurata  ;  Isamu Okamoto  ;  Caicun Zhou  ;  Ying Cheng  ;  Eun Kyung Cho  ;  Pei Jye Voon  ;  Jong-Seok Lee  ;  Helen Mann  ;  Matilde Saggese  ;  Thanyanan Reungwetwattana  ;  Suresh S. Ramalingam  ;  Yuichiro Ohe 
Citation
 JOURNAL OF THORACIC ONCOLOGY, Vol.14(1) : 99-106, 2019 
Journal Title
 JOURNAL OF THORACIC ONCOLOGY 
ISSN
 1556-0864 
Issue Date
2019
Keywords
Asian ; FLAURA ; First-line ; NSCLC ; Osimertinib
Abstract
INTRODUCTION: Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations. METHODS: Eligible Asian patients (enrolled at Asian sites) who were at least 18 years of age (≥20 years in Japan) and had untreated EGFR-mutated advanced NSCLC were randomized 1:1 to receive osimertinib (80 mg, orally once daily) or an SoC EGFR TKI (gefitinib, 250 mg, or erlotinib, 150 mg, orally once daily). The primary end point was investigator-assessed progression-free survival (PFS). The key secondary end points were overall survival, objective response rate, central nervous system efficacy, and safety. RESULTS: The median PFS was 16.5 versus 11.0 months for the osimertinib and SoC EGFR TKI groups, respectively (hazard ratio = 0.54, 95% confidence interval: 0.41-0.72, p < 0.0001). The overall survival data were immature (24% maturity). The objective response rates were 80% for osimertinib and 75% for an SoC EGFR TKI. The median central nervous system PFS was not calculable for the osimertinib group and was 13.8 months for the SoC EGFR TKI group (hazard ratio = 0.55, 95% confidence interval: 0.25-1.17, p = 0.118). Fewer adverse events of grade 3 or higher (40% versus 48%) and fewer adverse events leading to treatment discontinuation (15% versus 21%) were reported with osimertinib versus with an SoC EGFR TKI, respectively. CONCLUSION: In this Asian population, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over an SoC EGFR TKI, with a safety profile consistent with that for the overall FLAURA study population.
Full Text
https://www.sciencedirect.com/science/article/pii/S1556086418330910
DOI
10.1016/j.jtho.2018.09.004
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/167632
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse